Hematology and Oncology Studies
PPD’s hematology and oncology team shares your commitment in the fight against cancer. Our knowledge of hematology and oncology research, our vast capabilities and our experience with feasibility studies can significantly impact study efficiency and success. From January 2004 to July 2009, we conducted or supported 505 hematology/oncology protocols with approximately 77,500 patients and 15,900 sites.
Scientific and Medical Expertise
Our hematology and oncology experts across the globe ensure your trials stay on track at any phase of development, from discovery to late stage research. Our team includes:
- More than 4,000 staff worldwide with experience in hematology and oncology
- A senior medical director who provides critical scientific oversight with more than a decade of drug discovery and development expertise. He is board certified in internal medicine, hematology and medical oncology
- An international oncology advisory board that offers PPD clients valuable clinical insight and drug development consulting
Global Hematology and Oncology Investigator Network
Timely clinical trial startups count in the race against cancer. Our global network consists of more than 7,400 investigators with hematology and oncology experience, and we have close relationships and consulting agreements with physicians at most of the major tertiary and academic cancer centers. The network enables PPD to start and move quickly.
Hematology and Oncology Therapeutic Services
From individual clinical trials to the whole life cycle of your compound, let us help you with a strategy at any stage of development. We offer development-focused therapeutic experience from preclinical investigation through post-approval reporting:
- Investigator-initiated research protocols conducted in large cancer centers and local practices, including investigational new drug (IND) exempt and nonexempt trials:
- Non-small cell lung cancer
- Prostate cancer
- Breast cancer
- Ovarian cancer
- Therapeutic safety profiles focused on specific cellular targets that facilitate accelerated access to the market
- Late stage research capabilities, including:
- Phase IIIb-IV studies
- Safety surveillance studies
- Pharmacoepidemiology
- Risk management
- Observational studies
- Registries
